Fundraising Fox
/Companies
Sign in

Exonate - company

Founded 2013 · 17 employees on LinkedIn · 8 known investors

Find your way into Exonate - company

Sign up to see every warm intro you have to Exonate - company

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Exonate - company team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

OHOlav Hellebø
Olav HellebøChief Executive Officer

Investors · 8

Wellcome Trust✓ confirmed by Exonate - companyLondon

How we know: the company's own site · Not right? Tell us

Wren Capital✓ confirmed by Exonate - companyLondon

How we know: the company's own site · Not right? Tell us

Cambridge Angels grouplisted by Cambridge Angels groupCambridge · $195K – $1.9M

How we know: Cambridge Angels group's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

EMV Capitallisted by EMV CapitalLondon

How we know: EMV Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Martlet Capitallisted by Martlet CapitalCambridge · $317.5K
Stoic VClisted by Stoic VCSydney · $65K – $650K

How we know: Stoic VC's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

UniSeed Pty Ltd.listed by UniSeed Pty Ltd.Brisbane · $165K – $330K

How we know: UniSeed Pty Ltd.'s portfolio page · the VCSheet dataset · Not right? Tell us

Frequently asked questions

What does Exonate - company do?
Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.
Who are Exonate - company's investors?
Exonate - company's investors include O2h Ventures, Wellcome Trust, Wren Capital, Cambridge Angels group, EMV Capital, Martlet Capital, Stoic VC, UniSeed Pty Ltd..